复宏汉霖(02696.HK)帕妥珠单抗HLX11生物制品许可申请获FDA受理

阿斯达克财经
02 Feb

复宏汉霖(02696.HK) 公布,Perjeta(帕妥珠单抗)生物类似药候选药HLX11的生物制品许可申请获美国食品药品管理局“FDA”受理。HLX11是公司自主研发的帕妥珠单抗生物类似药,拟用于HER2阳性早期乳腺癌的新辅助/辅助治疗、HER2阳性转移性乳腺癌的治疗及/或与原研药药品标签相符的其他适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-28 12:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10